Clinical trials
Lung Cancer Patients clinical trials
Below are recruiting lung cancer patients clinical trials, each written for real people, not researchers. We’re tracking 1,902 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07514754Recruiting
Immunonutrition support during cancer treatment
This study tests whether special nutritional support (called immunonutrition) helps patients with head and neck, lung, or rectal cancer who are receiving chemotherapy, radiation, or immunotherapy. The goal is to see if it improves how well treatment works and how you feel during and after cancer care.
Candiolo, Torino (TO)Ages 18 years+ - NCT07538947Recruiting
Real-time imaging to diagnose lung cancer faster and safer
This trial tests a new camera tool (confocal laser endomicroscopy) that lets doctors see lung tissue in real-time during a biopsy procedure. The goal is to diagnose non-small cell lung cancer more quickly and safely than standard biopsies alone.
NancyAges 18 years+ - NCT07543601Recruiting
Better COPD care for people evaluated for lung cancer
This trial tests whether people being checked for possible lung cancer can also get improved care for a breathing condition called COPD (chronic obstructive pulmonary disease). It focuses on patients whose lung function tests show airflow problems.
VejleAges 18 years+ - NCT07563205Recruiting
Study of Chemotherapy and Amivantamab for Advanced Lung Cancer
This study follows patients with advanced lung cancer (a type called non-small cell lung cancer) who are receiving a combination of chemotherapy and a drug called amivantamab. Researchers want to understand how well this treatment works and track your health outcomes over time.
Aix-en-ProvenceAges 18 years+ - NCT07565532Recruiting
Small Cell Lung Cancer Treatment Study With Radiation
This study follows patients with small cell lung cancer who receive radiation therapy combined with other treatments. Researchers will track how well the treatment works and how patients respond over time to help improve future care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07603856RecruitingPhase 2
Combining Immunotherapy and Radiation for Advanced Lung Cancer
This study tests whether adding focused radiation therapy to immunotherapy can help patients with advanced non-small cell lung cancer whose cancer has progressed despite prior immunotherapy. The goal is to see if this combination works better than immunotherapy alone.
Chicago, IllinoisAges 18 years+ - NCT07617246RecruitingPhase 2
Preventing nausea from cancer treatment with new medications
This study tests two medications (fosrolapitant and palonosetron) to prevent severe nausea and vomiting in patients with esophageal or lung cancer who are receiving chemotherapy combined with immunotherapy. If the medications work well, they could help patients feel better during treatment and complete their cancer care more comfortably.
Hangzhou, ZhejiangAges 18 years+ - NCT07637474Recruiting
Immune System and Lung Cancer Response to Immunotherapy
This study looks at how your immune system works in non-small cell lung cancer and whether it predicts how well you'll respond to a type of immunotherapy called anti-PD-1/PD-L1 drugs. Researchers will study your tumor tissue to understand why some patients benefit more than others.
Rome, RomeAges 18 years+ - NCT07649629Recruiting
Blood test to help diagnose advanced lung cancer
This study tests whether a blood test (liquid biopsy) can help doctors better understand your lung cancer and plan your treatment. You'll have a blood sample taken alongside standard biopsies to see if the blood test provides useful information about your cancer.
Roma, RMAges 18 years+ - NCT07652736Recruiting
Tislelizumab for lung cancer in routine care
This study watches how well Tislelizumab works for people with lung cancer when it is used as part of their normal treatment. It does not give you any new medicine or change your care plan.
SegoviaAges 18 years+ - NCT07301983Enrolling by invitation
Testing a faster way to check lymph nodes in lung cancer surgery
This trial compares a new, quick test called OSNA to the standard method for checking lymph nodes in people with early-stage lung cancer who are having robotic surgery. The goal is to see if the new test works as well or better.
Pisa, PisaAges 18 years+ - NCT07285434Enrolling by invitationEarly Phase 1
Personalized vaccine for first-line advanced lung cancer
This study tests a personalized vaccine (Microlyvaq™) made just for your tumor, given together with standard chemo and immunotherapy (pembrolizumab). It is for people with advanced non-small cell lung cancer who have not yet started treatment for the advanced stage.
Thessaloniki, MacedoniaAges Any age - NCT06962449Enrolling by invitation
Study of Tislelizumab as First Treatment for Advanced Lung Cancer
This study looks at how well Tislelizumab works as the first treatment for advanced non-small cell lung cancer that has spread. It aims to understand which treatment strategies after Tislelizumab lead to the best survival outcomes for patients.
Shanghai, Shanghai MunicipalityAges Any age - NCT06883136Enrolling by invitation
Sintilimab plus chemo for elderly advanced lung cancer
This trial tests a combination of the immunotherapy drug sintilimab plus standard chemotherapy (platinum-based doublet) as the first treatment for older adults (60–80) with advanced non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach works better than chemotherapy alone.
Jinan, ShandongAges 60–80 - NCT06730685Enrolling by invitation
Sarcopenia and cachexia in lung cancer patients
This study looks at muscle loss (sarcopenia) and weight loss (cachexia) in people with lung cancer. Researchers want to understand these conditions better to improve care.
Næstved, Region SjællandAges 18 years+ - NCT06250777Enrolling by invitationPhase 2
T-DXd for HER2-mutant lung cancer with brain metastases
This trial tests a drug called T-DXd in people with advanced non-squamous lung cancer that has a specific HER2 gene change (mutation) and has spread to the brain but isn't causing symptoms. The goal is to see if the drug can shrink tumors and help control the cancer.
SeoulAges 20 years+ - NCT00471978Recruiting
Analyzing DNA from blood and lung tumor tissue
This study looks at DNA from blood samples and lung tumor tissue in people newly diagnosed with primary lung cancer. The goal is to learn more about the cancer’s biology and possibly guide better future care.
Boston, MassachusettsAges 18–120 - NCT07472517RecruitingPhase 3
Obrixtamig plus standard therapy for advanced small cell lung cancer
This trial tests whether adding a new drug, obrixtamig, to the usual first treatment for extensive-stage small cell lung cancer can help people live longer or slow the cancer's growth. The usual treatment is a combination of atezolizumab, carboplatin, and etoposide.
Mobile, AlabamaAges 18 years+ - NCT06992583RecruitingPhase 1
CAR-T cell therapy for advanced CEA-positive lung cancer
This trial tests a new type of immune therapy called CAR-T cells that are designed to attack lung cancer cells with a specific marker called CEA. It may be an option for people with advanced lung cancer who have already tried other treatments.
Nanjing, JiangsuAges 18 years+ - NCT06945523RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced lung cancer
This trial tests a treatment using your own immune cells, modified to target a protein called CEA on lung cancer cells. It's for people with advanced lung cancer that has gotten worse after at least one prior treatment.
Wuhan, HubeiAges 18 years+ - NCT07107490RecruitingPhase 1
Study of ALPS12 for advanced small cell lung cancer
This study tests a new drug called ALPS12 for people with extensive-stage small cell lung cancer that has come back after at least one prior treatment. It aims to see if the drug is safe and effective.
Hong KongAges 18 years+ - NCT06768151RecruitingPhase 1
CEA-targeting car-t therapy for advanced lung cancer
This trial tests a new treatment called CAR-T therapy that targets a protein called CEA found on some lung cancer cells. It is for people with advanced lung cancer that has not responded to or has gotten worse after at least two standard treatments.
Wuhan, HubeiAges 18 years+ - NCT07517692Enrolling by invitation
Improving shared decision-making for lung cancer screening
This study tests a new way to help patients and doctors discuss lung cancer screening together using text messages and shared decision-making tools. It may help you understand screening options better and make choices that fit your values.
Worcester, MassachusettsAges 50–77 - NCT06183762Recruiting
Real-world study of treatments for MET-mutation lung cancer
This study looks at how different treatments work for people with advanced lung cancer that has a MET mutation. It aims to understand real-world treatment patterns and outcomes to help guide future care.
Changsha, HunanAges 18 years+
Hear when a new Lung Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer patients?
- Yes. Clin2 currently lists 1,902 recruiting lung cancer patients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer patients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer patients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.